CompletedNCT03448705Updated Mar 3, 2021

Safety of 4Fluart ID Suspension for Injection in Adult Subjects

A Phase 1 interventional study of 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted) and 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted) in Human Influenza, sponsored by Fluart Innovative Vaccine Ltd, Hungary. Completed at 1 site in Hungary. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Fluart Innovative Vaccine Ltd, Hungary · Phase 1, Interventional, and Prevention

Phase: Phase 1
Study type: Interventional
Enrollment: 36
Allocation: Randomized
Ages: 18 Years to 59 Years
Sex: All

Study summary

The primary objective of the study is to evaluate the safe usability of the study drugs, i.e. 4Fluart ID 1 µg haemagglutinin (HA)/0.1 ml QIV and 4Fluart ID 2 µg haemagglutinin (HA)/0.1 ml QIV in terms of safety concerns emerged.

The secondary objective of the study is to further assess safety in terms of safety parameters, as well as to assess the immunogenicity of 4Fluart ID 1 µg haemagglutinin (HA)/0.1 ml QIV and 4Fluart ID 2 µg haemagglutinin (HA)/0.1 ml QIV in terms of immunogenicity parameters.

Read the detailed description

Healthy volunteers (male and female) aged 18-59 years were enrolled into the study by signing subject information leaflet and informed consent form. After screening them, subjects complying with inclusion and exclusion criteria were included in the study, randomised and vaccinated with one of the investigational medicinal products assigned by the randomisation list.

Subjects were observed for thirty (30) minutes after vaccination for any immediate reactions. All adverse events (AEs) were collected from the enrolment to Day 21-28. Safety data between Day 0 and Day 7-9 were documented on a Diary card by each subject. Safety assessment were performed based on Day 7-9 and Day 21-28 safety data compared to the baseline on Day 0.

Blood samples for immunogenicity assays were collected immediately before vaccination on Day 0 (pre-vaccination blood samples) and on Day 21-28 (post-vaccination blood samples) in all subjects included in the study and complying with the study procedures. Immunogenicity were evaluated by hemagglutinin inhibition test in order to assess immune response 3-4 weeks after vaccination.

The assessment of safety and immunogenicity of 4Fluart ID 1 µg/0.1 ml QIV and 4Fluart ID 2 µg/0.1 ml QIV was performed in comparison to the authorised 3Fluart, i.e. 3Fluart intramuscular (IM) 6 µg/0.5 ml TIV.

Conditions studied

Human Influenza

Browse trials for

Influenza, Human 2,209

Keywords

influenza

Who can participate

Ages eligible: 18 Years to 59 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Adult persons aged 18 to 59 years, determined on the day of enrolment from both sexes, mentally competent;
Good health (as determined by vital signs and existing medical condition) or stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or insulin treated), the significance of which, in the opinion of the investigator, will not compromise the subject's participation in the study;
Female volunteers of childbearing potential upon the decision of the investigator with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and to not become pregnant for the duration of the study;
Capability of participants to understand and comply with planned study procedures;
Participants provide written informed consent prior to initiation of study procedures;
Absence of any exclusion criteria.

Exclusion criteria

Exclusion Criteria:

Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study. Pregnancy with regard to the total duration of the study.
Hypersensitivity to the active substances or to any of the excipients, such as thiomersal, or any component that may be present in traces, such as egg (ovalbumin), formaldehyde, gentamicin, neomycin, vancomycin or ciprofloxacin determined prior to vaccination;
Serious complications in the medical history with regard to any previous vaccination: encephalitis/encephalopathy, nonfebrile seizures, Guillain-Barré syndrome, vasculitis, neuritis, facial paresis determined prior to vaccination;
History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine determined prior to vaccination;
Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure with regard to the total duration of the study;
Immunosuppressive therapy within 36 months prior to vaccination and with regard to the total duration of the study;
Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids with regard to the total duration of the study;
Receipt of immunostimulants with regard to the total duration of the study;
Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within 3 months prior to vaccination and with regard to the total duration of the study;
Suspected or known HIV, Hepatitis-B virus (HBV) or Hepatitis-C virus (HCV) infection with regard to the total duration of the study;
Acute disease and/or axillary temperature ≥37oC within 3 days prior to vaccination;
Vaccine therapy within 4 weeks prior to vaccination and with regard to the total duration of the study;
Influenza vaccination (any kind) within 6 months prior to vaccination and with regard to the total duration of the study;
Experimental drug therapy within 4 weeks prior to vaccination and with regard to the total duration of the study;
Concomitant participation in another clinical study;
Any condition which, may interfere with the evaluation of the study (including major protocol deviation with regard to the total duration of the study);
Past or current psychiatric disease of the volunteer that upon judgement of the investigator may have an effect on the objective decision-making of the volunteer;
Alcohol or drug abuse of the participant.

Study design

Phase: Phase 1
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Single (Participant)
Enrollment: 36 participants (actual)

Study arms

Experimental
Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)
Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
Biological: 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Experimental
Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)
Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
Biological: 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Active comparator
Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)
Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
Biological: 3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)

Interventions

Biological4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
Also known as: 4Fluart ID suspension for injection study drug, 4Fluart ID 1 µg/0.1 ml QIV
Biological4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
Also known as: 4Fluart ID suspension for injection study drug, 4Fluart ID 2 µg/0.1 ml QIV
Biological3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)
Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
Also known as: 3Fluart suspension for injection, 3Fluart IM 6 µg/0.5 ml TIV

What researchers measure

Primary outcomes

Safety in terms of safety concenrs emerged
Percentage of subjects reporting safety concerns following vaccination Measurement is based on the assessment of the study investigator by each subject
Time frame: Between 0 day (day of vaccination) and 21-28 days after vaccination

Secondary outcomes

Ratio of geometric mean anti-hemagglutinin antibody titres, for A/H1N1, A/H3N2, B strains
Ratio of Day 21-28 and Day 0 titres Anti-hemagglutinin antibodies are measured by hemagglutinin inhibition test
Time frame: Between 0 day (day of vaccination) and 21-28 days after vaccination
Percentage of subjects seroconverted based on anti-hemagglutinin antibody titres, for A/H1N1, A/H3N2, B strains
Seroconversion is defined as in subjects seronegative at baseline (i.e. HI titre \<1:10 at Day 0) a post-vaccination HI titre ≥1:40, and in subjects seropositive at baseline (i.e. HI titre ≥1:10 at Day 0) as minimum of a 4-fold increase in post-vaccination HI titre Anti-hemagglutinin antibodies are measured by hemagglutinin inhibition test
Time frame: 0 days (day of vaccination) and 21-28 days after vaccination
Percentage of subjects seroprotected based on anti-hemagglutinin antibody titres, for A/H1N1, A/H3N2, B strains
The seroprotection rate is defined as a proportion of subjects with HI titre ≥1:40. Anti-hemagglutinin antibodies are measured by hemagglutinin inhibition test
Time frame: 0 days (day of vaccination) and 21-28 days after vaccination

Study locations

1 site

Drug Research Center
Balatonfüred, Veszprém H-8230, Hungary

Registry details

Key details

Study ID: NCT03448705
Lead sponsor: Fluart Innovative Vaccine Ltd, Hungary
Responsible party: Sponsor
First posted: Feb 28, 2018
Start date: Jan 31, 2018
Primary completion: Apr 3, 2018
Completion: Apr 3, 2018
Last update: Mar 3, 2021

Study contacts

Orsolya Gyurján

study director · Fluart Innovative Vaccines Ltd.

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Influenza, Human→

Other studies from this sponsor

Fluart Innovative Vaccine Ltd, Hungary

Start the discussion